HealthDay News

GU Oncology Now

Magnetic resonance imaging-apparent diffusion coefficient (MRI-ADC) and 68 gallium [68Ga]Ga-prostate-specific membrane antigen (PSMA)-11 positron emission tomography (PET) imaging can differentiate International Society of Urological Pathology (ISUP) grade 1 patients, with clinically nonsignificant prostate cancer, from ISUP grade 2+ patients, according to a study published online April 8 in&nbsp;Cancers.Giacomo Feliciani, from IRCCS Istituto Romagnolo per lo Studio dei Tumori in Meldola, Italy, and colleagues applied radiomics analysis to MRI-ADC and [68Ga]Ga-PSMA-11 PET to quantify tumor characteristics and predict ISUP grades in 28 patients. Predictive models based on imaging features were trained on 31 lesions to differentiate ISUP grade 1 patients from ISUP grade 2+ patients.The researchers found that the best model based on [68Ga]Ga-PSMA-11 PET had prediction efficiency of 95 and 100 percent in the training and test phases, respectively; the best model based on MRI-ADC had efficiency of 100 percent in both phases. Prediction efficiency was 100 and 93 percent in the training and test phases, respectively, when employing both models.&ldquo;Preliminary results suggest that aside from the MRI-ADC average value, currently employed in clinical practice to assess lesion severity, other imaging biomarkers may provide complementary information for ISUP grade prediction, but further, broader studies are necessary to confirm these findings,&rdquo; the authors write. &ldquo;Both [68Ga]Ga-PSMA-11 PET and MRI-ADC imaging biomarkers showed to be complementary in ISUP grade assessment when employed together to build prediction models.&rdquo;Source: HealthDay News

MRI-ADC, [⁶⁸Ga]Ga-PSMA-11 PET Can Differentiate ISUP Grades

Radioligand therapy prostate-specific membrane antigen

About Us

Contributors and Partners

Editorial Policy

Advertising

eNewsletters

Calendar

Contact Us

Contribute

MashupMD

Cancer Nursing Today

Urban Health Today

Blood Cancers Today

DocWire News

Knowledge Hubs

Conference Coverage

Roundtables

The Uromigos

Uromigos Live 2024

AUC3

Localized

mHSPC/mCSPC

CRPC

Diagnostics

Prostate Cancer

Localized Renal Cell Carcinoma

Advanced Renal Cell Carcinoma

nccRCC

Renal Cell Carcinoma

Non-Muscle Invasive Urothelial Carcinoma

Muscle Invasive Urothelial Carcinoma

Advanced Urothelial Carcinoma

Upper Tract Urothelial Carcinoma

Urothelial Carcinoma

Testicular, Penile, and Rare Cancers

Video Insights

Advancements in Oncology

The Oncology Brothers

Expert Interviews

Journal

Subscribe